IDEAYA Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion H2 2026
· seekingalpha.com
IDEAYA Biosciences nears a 2026 melanoma drug filing, backed by strong clinical data and cash into 2030. Read why IDYA stock is a strong buy.
Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from...